We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary arterial hypertension (PAH) in rats, a study reports. “This study offers a fresh ...

Tectonic Therapeutic (NASDAQ:TECX) recently announced positive interim results from its phase 1b study using Fc-fusion protein TX45 for the treatment of patients with Group 2 pulmonary ...

In related news, Tectonic Therapeutics has been under scrutiny after Eli Lilly halted a phase 2 clinical trial for a drug similar to Tectonic’s TX45. Despite this, Leerink Partners maintained ...

The capital is earmarked for the clinical development of Tectonic's TX45 and TX2100, as well as for enhancing their discovery platform, in addition to providing working capital and supporting ...

Nvidia (NASDAQ: NVDA) CEO Jensen Huang’s meeting with President Donald Trump on Friday capped a whirlwind week for the increasingly life sciences-focused Silicon Valley microprocessing giant, in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key clinical candidates for these companies: ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...

TX-000045 is under clinical development by Tectonic Therapeutic Inc and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase II drugs for Pulmonary Hypertension have a 58% ...

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered ...